Federal Register / Vol. 77, No. 41 / Thursday, March 1, 2012 / Notices 12621 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on 

December 30, 2011, Mylan 

Pharmaceuticals, Inc., 781 Chestnut 

Ridge Road, Morgantown, West Virginia 

26505, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

the following basic classes of controlled 

substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

The company plans to import the 

listed controlled substances in finished 

dosage form (FDF) from foreign sources 

for analytical testing and clinical trials 

in which the foreign FDF will be 

compared to the company’s own 

domestically-manufactured FDF. This 

analysis is required to allow the 

company to export domesticallymanufactured FDF to foreign markets. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances may file comments or 

objections to the issuance of the 

proposed registration and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43, and in such form as 

prescribed by 21 CFR 1316.47. 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than April 2, 2012. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

40 FR 43745–46, all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: February 23, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–4992 Filed 2–29–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration; Mylan 

Pharmaceuticals Inc. 

By Notice dated December 22, 2011, 

and published in the Federal Register 

on December 29, 2011, 76 FR 81978, 

Mylan Pharmaceuticals, Inc., 781 

Chestnut Ridge Road, Morgantown, 

West Virginia 26505, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the following basic 

classes of controlled substances: 

Drug Schedule 

Methylphenidate (1724) ................ II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Fentanyl (9801) ............................ II 

The company plans to import the 

listed controlled substances in finished 

dosage form (FDF) from foreign sources 

for analytical testing and clinical trials 

in which the foreign FDF will be 

compared to the company’s own 

domestically-manufactured FDF. This 

analysis is required to allow the 

company to export domesticallymanufactured FDF to foreign markets. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a), 

and determined that the registration of 

Mylan Pharmaceuticals, Inc. to import 

the basic classes of controlled 

substances is consistent with the public 

interest, and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971. DEA has investigated 

Mylan Pharmaceuticals, Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: February 23, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–4994 Filed 2–29–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Parole Commission 

Sunshine Act Meeting 

TIME AND DATE: 1:30 p.m., Thursday, 

March 8, 2012. 

PLACE: U.S. Parole Commission, 90 K 

Street NE., 3rd Floor, Washington, DC. 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: 

Consideration of two original 

jurisdiction cases pursuant to 28 CFR 

2.27. 

CONTACT PERSON FOR MORE INFORMATION: 

Patricia W. Moore, Staff Assistant to the 

Chairman, U.S. Parole Commission, 90 

K Street NE., 3rd Floor, Washington, DC 

20530, (202) 346–7001. 

Dated: February 27, 2012. 

Rockne Chickinell, 

General Counsel, U.S. Parole Commission. 

[FR Doc. 2012–5183 Filed 2–28–12; 4:15 pm] 

BILLING CODE 4410–31–P 

MISSISSIPPI RIVER COMMISSION 

Sunshine Act Meetings 

AGENCY: Agency Holding the Meetings: 

Mississippi River Commission. 

DATES: Time and Date: 9 a.m., March 26, 

2012. 

Place: On board MISSISSIPPI V at 

River Park, Tiptonville, TN. 

Status: Open to the public. 

Matters To Be Considered: (1) 

Summary report by President of the 

Commission on national and regional 

issues affecting the U.S. Army Corps of 

Engineers and Commission programs 

and projects on the Mississippi River 

and its tributaries; (2) District 

Commander’s overview of current 

project issues within the Memphis 

District; and (3) Presentations by local 

organizations and members of the 

public giving views or comments on any 

issue affecting the programs or projects 

of the Commission and the Corps of 

Engineers. 

mstockstill on DSK4VPTVN1PROD with NOTICES